Burning Rock Biotech Limited (BNR)Healthcare | Diagnostics & Research | Guangzhou, China | NasdaqGM
10.19 USD
+0.19
(1.900%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 10.08 -0.11 (-0.110%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:43 a.m. EDT
The immediate outlook remains neutral due to a lack of clear directional momentum, despite a recent bounce off the lows. While the stock has recovered significantly from its multi-year collapse, the underlying business fundamentals are severely impaired, making it a poor candidate for long-term holding. The company is generating negative free cash flow, posting widening operating losses, and suffering from an 18.9% decline in revenue. Although the CEO has been buying shares recently, signaling some internal confidence, this cannot offset the structural deterioration where the business is shrinking and burning cash. Furthermore, there is no dividend to provide income, and the valuation metrics reflect a deep skepticism about future profitability. The statistical forecast offers no guidance, leaving investors exposed to a speculative biotech play with no earnings floor. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.094662 |
| AutoETS | 0.107351 |
| AutoARIMA | 0.133738 |
| AutoTheta | 0.139132 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.15 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.616 |
| Excess Kurtosis | 0.03 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 9.848 |
| Revenue per Share | 48.669 |
| Market Cap | 107,467,232 |
| Forward P/E | -17.57 |
| Beta | 1.38 |
| Profit Margins | -11.53% |
| Website | https://www.brbiotech.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.29974484 |
| Address1 | No. 5, Xingdao Ring Road North |
| Address2 | International Bio Island |
| All Time High | 397.5 |
| All Time Low | 2.18 |
| Ask | 11.48 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 7,820 |
| Average Daily Volume3 Month | 16,969 |
| Average Volume | 16,969 |
| Average Volume10Days | 7,820 |
| Beta | 1.379 |
| Bid | 6.35 |
| Bid Size | 2 |
| Book Value | 7.305385 |
| City | Guangzhou |
| Country | China |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 10.19 |
| Current Ratio | 3.05 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 10.2 |
| Day Low | 9.79 |
| Debt To Equity | 9.848 |
| Display Name | Burning Rock Biotech |
| Earnings Call Timestamp End | 1,716,984,000 |
| Earnings Call Timestamp Start | 1,716,984,000 |
| Earnings Timestamp End | 1,749,211,200 |
| Earnings Timestamp Start | 1,749,034,740 |
| Ebitda | -44,327,752 |
| Ebitda Margins | -0.086169995 |
| Enterprise To Ebitda | 6.496 |
| Enterprise To Revenue | -0.56 |
| Enterprise Value | -287,944,416 |
| Eps Forward | -0.58 |
| Eps Trailing Twelve Months | -0.85 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.42436 |
| Fifty Day Average Change | 0.7656393 |
| Fifty Day Average Change Percent | 0.08124045 |
| Fifty Two Week Change Percent | 29.974483 |
| Fifty Two Week High | 41.72 |
| Fifty Two Week High Change | -31.530003 |
| Fifty Two Week High Change Percent | -0.7557527 |
| Fifty Two Week Low | 6.79 |
| Fifty Two Week Low Change | 3.3999996 |
| Fifty Two Week Low Change Percent | 0.5007363 |
| Fifty Two Week Range | 6.79 - 41.72 |
| Financial Currency | CNY |
| First Trade Date Milliseconds | 1,591,968,600,000 |
| Float Shares | 3,309,778 |
| Forward Eps | -0.58 |
| Forward P E | -17.568966 |
| Free Cashflow | -18,967,500 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 667 |
| Fullday Change | 0.19 |
| Fullday Change Percent | 1.9 |
| Fullday Price | 10.08 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.74553 |
| Gross Profits | 383,520,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.040149998 |
| Held Percent Institutions | 0.46953 |
| Implied Shares Outstanding | 10,546,343 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,715,731,200 |
| Last Split Factor | 1:10 |
| Long Business Summary | Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China. |
| Long Name | Burning Rock Biotech Limited |
| Market | us_market |
| Market Cap | 107,467,232 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_309457193 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -59,318,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 105,463,429 |
| Open | 9.79 |
| Operating Cashflow | -34,220,000 |
| Operating Margins | -0.17458001 |
| Payout Ratio | 0.0 |
| Phone | 86 20 3403 7871 |
| Post Market Change | -0.10999966 |
| Post Market Change Percent | -1.0794864 |
| Post Market Price | 10.08 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 10.0 |
| Price Hint | 2 |
| Price To Book | 1.3948613 |
| Price To Sales Trailing12 Months | 0.20890586 |
| Profit Margins | -0.11531 |
| Quick Ratio | 2.712 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.18999958 |
| Regular Market Change Percent | 1.8999958 |
| Regular Market Day High | 10.2 |
| Regular Market Day Low | 9.79 |
| Regular Market Day Range | 9.79 - 10.2 |
| Regular Market Open | 9.79 |
| Regular Market Previous Close | 10.0 |
| Regular Market Price | 10.19 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 28,909 |
| Return On Assets | -0.04453 |
| Return On Equity | -0.10901 |
| Revenue Growth | -0.189 |
| Revenue Per Share | 48.669 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 8,813,858 |
| Shares Percent Shares Out | 0.0037 |
| Shares Short | 39,450 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 44,821 |
| Short Name | Burning Rock Biotech Limited |
| Short Percent Of Float | 0.0055 |
| Short Ratio | 5.55 |
| Source Interval | 15 |
| Symbol | BNR |
| Total Cash | 446,001,984 |
| Total Cash Per Share | 42.397 |
| Total Debt | 50,863,000 |
| Total Revenue | 514,428,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.85 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 17.585184 |
| Two Hundred Day Average Change | -7.3951845 |
| Two Hundred Day Average Change Percent | -0.42053494 |
| Type Disp | Equity |
| Volume | 28,909 |
| Website | https://www.brbiotech.com |
| Zip | 510,005 |